Bank of Montreal Can Takes $540,000 Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Bank of Montreal Can acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,936 shares of the company’s stock, valued at approximately $540,000.

A number of other hedge funds also recently bought and sold shares of the stock. Jamison Private Wealth Management Inc. purchased a new stake in shares of Krystal Biotech during the 2nd quarter worth $28,000. GAMMA Investing LLC lifted its holdings in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the last quarter. Key Financial Inc acquired a new position in Krystal Biotech during the 2nd quarter valued at about $28,000. Blue Trust Inc. boosted its holdings in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Krystal Biotech during the second quarter valued at about $71,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 14.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

KRYS has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Chardan Capital upped their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Stifel Nicolaus lifted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Finally, HC Wainwright raised their price objective on Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $196.75.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $174.84 on Wednesday. The company has a 50 day moving average price of $188.84 and a 200-day moving average price of $179.98. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $219.34. The firm has a market cap of $4.99 billion, a price-to-earnings ratio of 93.50 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The firm had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. Krystal Biotech’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.25) EPS. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 3.13 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).